Fagiolini, Andrea

English

PubMed

Andrea Fagiolini

Crossref

MEETING ABSTRACT Open Access
Aripiprazole in bipolar disorder: clinical strategies
to maximize efficacy and tolerability
Andrea Fagiolini
From 1st International Congress on Neurobiology and Clinical Psychopharmacology and European
Psychiatric Association Conference on Treatment Guidance
Thessaloniki, Greece. 19-22 November 2009
A number of double-blind, randomized, controlled trials
have confirmed the clinical efficacy of aripiprazole in
bipolar disorder and schizophrenia. Aripiprazole is the
prototype of the ‘third generation’ atypical antipsycho-
tics, or dopamine-serotonin- stabilizers and is character-
ized by a relatively low risk of inducing metabolic
adverse effects, causing sedation and other side effects
such as hyperprolactinemia. As a partial agonist at dopa-
mine D2 receptors, aripiprazole acts as a functional
antagonist in the mesolimbic dopamine pathway, where
excessive dopamine activity is thought to cause positive
symptoms, but acts as a functional agonist activity in
the mesocortical pathway, where reduced dopamine
activity is thought to be associated with negative symp-
toms and cognitive impairment. This presentation will
review the available research data on the efficacy of ari-
piprazole in bipolar disorder and discuss how this data
translate in the real world clinical practice and what the
best strategies are to maximize the efficacy and toler-
ability of this medication.
Published: 22 April 2010
doi:10.1186/1744-859X-9-S1-S60
Cite this article as: Fagiolini: Aripiprazole in bipolar disorder: clinical
strategies to maximize efficacy and tolerability. Annals of General
Psychiatry 2010 9(Suppl 1):S60.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Division of Psychiatry, University of Siena School of Medicine, Siena, Italy
Fagiolini Annals of General Psychiatry 2010, 9(Suppl 1):S60
http://www.annals-general-psychiatry.com/content/9/S1/S60
© 2009 Fagiolini; licensee BioMed Central Ltd.


Aripiprazole in bipolar disorder: clinical strategies to maximize efficacy and tolerability

A number of double-blind, randomized, controlled trials have confirmed the clinical efficacy of aripiprazole in
bipolar disorder and schizophrenia. Aripiprazole is the prototype of the ‘third generation’ atypical antipsychotics, or dopamine-serotonin- stabilizers and is characterized by a relatively low risk of inducing metabolic
adverse effects, causing sedation and other side effects such as hyperprolactinemia. As a partial agonist at dopamine D2 receptors, aripiprazole acts as a functional antagonist in the mesolimbic dopamine pathway, where excessive dopamine activity is thought to cause positive symptoms, but acts as a functional agonist activity in the mesocortical pathway, where reduced dopamine activity is thought to be associated with negative symptoms and cognitive impairment. This presentation will review the available research data on the efficacy of aripiprazole in bipolar disorder and discuss how this data translate in the real world clinical practice and what the best strategies are to maximize the efficacy and tolerability of this medication

Fagiolini, A.

Archivio della Ricerca - Università degli Studi di Siena

Aripiprazole in bipolar disorder: clinical strategiesto maximize efficacy and tolerability

Springer - Publisher Connector

Fagiolini Andrea

Directory of Open Access Journals

Annals of General Psychiatry

https://annals-general-psychiatry.biomedcentral.com/track/pdf/10.1186/1744-859X-9-S1-S60?site=annals-general-psychiatry.biomedcentral.com

Aripiprazole in bipolar disorder: clinical strategies to maximize efficacy and tolerability

Abstract

Similar works

Full text

Available Versions

Crossref

Archivio della Ricerca - Università degli Studi di Siena

Springer - Publisher Connector

Directory of Open Access Journals

Springer - Publisher Connector